Atlas Trials

EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS

Clinical trial NCT02907320 · WITHDRAWN

Trial details

NCT number
NCT02907320
Sponsor
Pierre Fabre Medicament
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Venous Disease Classification (CEAP): C2 or C3
Start date
2016-12-01
Primary completion
2018-05-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.